You are here

Development of an Angiogenic T Cell Assay for Personalized Cytomics in Cardiovasc

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL121904-01
Agency Tracking Number: R43HL121904
Amount: $222,916.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3160 CHESTNUT STREET SUITE 200
PHILADELPHIA, PA 19104-2850
United States
DUNS: 965026417
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 TODD JOHNSON
 (215) 573-4504
 todd.johnson@cytovas.com
Business Contact
 DORA MITCHELL
Phone: (215) 573-4504
Email: doram@upenn.edu
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): The goal of this research is to develop a new flow cytometry-based test for the clinical measurement of proangiogenic T cells. Such an assay does not exist today. Proangiogenic T cells, including angiogenic T cell (Tang) and Th17 subsets, participate in reparative mechanisms in the vasculature, in oncogenic angiogenesis and in other processes central to the overall health of the vascular system. The T cell test could be deployed as a stand-alone diagnostic tool but willultimately provide the final core module of the Cytometric Vascular Health Profile (CytoVasHP), a cell-based blood test for the assessment of vascular health. The cardiovascular community has realized that patients who present with similar risk of cardiovascular disease often end up developing (or not) a range of pathologies with different morbidity, mortality and responses to therapy. To determine the most effective care for individual patients and to identify those most likely to benefit from specifi

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government